CGEM Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 112424 min ago

@ $17.99

Išleistas: 14 vas. 2024 @ 22:07

Grąža: 53.31%

Ankstesnis signalas: vas. 14 - 21:44

Ankstesnis signalas: Pirkimas

Grąža: 1.47 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States...

Stats
Šios dienos apimtis	711 324
Vidutinė apimtis	690 940
Rinkos kapitalizacija	1.19B
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $-0.880 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.47
ATR14	$0.0510 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	Fenton Mary Kay	Buy	200 000	Stock Option (Right to Buy)
2024-04-29	Fenton Mary Kay	Buy	0
2024-03-29	Nguyen Nate	Sell	0	Common Stock
2024-03-29	Nguyen Nate	Sell	0	Common Stock
2024-03-29	Nguyen Nate	Sell	26 750	Stock Option (Right to Buy)

INSIDER POWER
-17.19
Last 98 transactions
Buy: 2 707 515 \| Sell: 6 664 307

Tūris Koreliacija

Ilgas: 0.12 (neutral)

Trumpas: 0.29 (neutral)

Signal:(53.809) Neutral

Cullinan Oncology, LLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
METC	0.827
RXRX	0.825
FSTR	0.822
AMTX	0.81
NTNX	0.805
TEAM	0.803
SNAX	0.802

10 Labiausiai neigiamai susiję koreliacijos
BNIXU	-0.831
PODD	-0.808

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Cullinan Oncology, LLC Koreliacija - Valiuta/Žaliavos

0.25
( neutral )

0.24
( neutral )

0.00
( neutral )

0.22
( neutral )

-0.52
( weak negative )

-0.17
( neutral )

Cullinan Oncology, LLC Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-310 000 (0.00 %)
EPS:	$-3.69

FY	2023
Pajamos:	$0
Bruto pelnas:	$-310 000 (0.00 %)
EPS:	$-3.69

FY	2022
Pajamos:	$0
Bruto pelnas:	$-93 000.00 (0.00 %)
EPS:	$2.46

FY	2021
Pajamos:	$18 943.00
Bruto pelnas:	$18 943.00 (100.00 %)
EPS:	$-0.00157

Financial Reports:

No articles found.

Cullinan Oncology, LLC

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.